Comparison of prevalence and clinical outcomes between types of study sites
| All sites (n=25) | Type 1 sites* (n=14) | Type 2 sites† (n=11) | |
| No of screened newborns | 21 272 | 14 642 | 6630 |
| No of congenitally infected cases | 66 | 35 | 31 |
| Prevalence of congenital infection, % (95% CI) | 0.31 (0.24 to 0.40) | 0.24 (0.16 to 0.32) | 0.47 (0.30 to 0.63) |
| Abnormalities identified within 3 months after birth | |||
| A: typical clinical manifestations at birth | 22.7% (n=15) | 8.6% (n=3) | 38.7% (n=12) |
| B: abnormalities in brain images (CT/MRI) | 15.2% (n=10) | 11.4% (n=4) | 19.4% (n=6) |
| A and/or B | 30.3% (n=20) | 17.1% (n=6) | 45.2% (n=14) |
| Treated with antiviral drugs | 9.1% (n=6) | 0.0% | 22.6% (n=6) |
| Detectable cytomegalovirus-IgM in blood of the cases | 50.8% (30/59) | 51.6% (16/31) | 50% (14/28) |
* Primary obstetric clinics and municipal hospitals.
† University-associated and governmental hospitals that care for general populations as well as patients referred from type 1 clinics.